Otsuka to Terminate Development of AVP-786

TOKYO & PRINCETON, N.J.--(BUSINESS WIRE)--Otsuka Pharmaceutical Co., Ltd. (Otsuka) and its U.S. subsidiary, Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) announce termination of development of the novel compound AVP-786, which was in development as a potential treatment for patients with agitation associated with dementia due to Alzheimer's disease. Otsuka initiated Phase 3 clinical trials for AVP-786. In the top-line results of the Phase 3 trial NCT03393520 (#305 trial